WebIntroduction: The aim of this multicenter phase II trial was to evaluate the combination of oral vinorelbine and cisplatin with radiotherapy (RT) after cisplatin-docetaxel induction chemotherapy (CT) in patients with locally advanced non-small cell lung cancer (NSCLC). Patients and methods: Patients with previously untreated, inoperable, histologically or … WebRandomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer. Author links open overlay panel E.H. Tan a, A. Szczesna b, M. Krzakowski c, H.N. Macha d, ...
Randomized study of vinorelbine–gemcitabine versus vinorelbine ...
WebDec 1, 1992 · The Journal of Clinical Pharmacology. Vinorelbine (NVB) is a new anticancer drug belonging to the vinca alkaloid family that shows activity as a single‐agent treatment in advanced non‐small cell Jung cancer (NSCLC). Preliminary results show a better response rate with a combination of cisplatin (CDDP) and NVB than with NVB alone. WebOct 2, 1997 · Cisplatin was started at 100 mg/m 2, given on days 1 and 22. Vinorelbine was started at 20 mg/m 2, given on days 1, 8, 15, 22, 29, and 36. Standard chest … dark cabinet with lagoon
Cisplatin and Vinorelbine permanent side effects - Lung cancer …
WebBackground: Cisplatin and vinorelbine given intravenously is a well-established adjuvant chemotherapy regimen after surgery for early non-small cell lung cancer. However, few validated alternatives exist when cisplatin is not indicated or tolerated. Carboplatin is frequently used in this setting. WebPatients should be advised to drink at least 2 litres of fluid over the 24 hours following cisplatin. Oral vinorelbine Vinorelbine is available as 20mg, 30mg and 80mg capsules. The capsules should be swallowed whole with water and with or after food. Equivalent doses: IV vinorelbine PO vinorelbine 30mg/m2 280mg/m 25mg/m 2 60mg/m WebOct 2, 1997 · Although cisplatin and vinorelbine have been widely used in the treatment of advanced non-small-cell lung cancer, there is a lack of consensus concerning the best regimen. This lack of consensus reflects the fact that improvement in outcome with vinorelbine alone or in combination, although clinically significant, remains modest. biscuits and gravy at ihop